Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C
- PMID: 11429157
- DOI: 10.1089/107999001300177457
Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C
Abstract
Chronic hepatitis is often associated with neuropsychiatric disorders. Interferon (IFN) is the drug most widely used to treat this disease, and its side effects, such as depression, often involve the central nervous system (CNS). Symptoms include a slowing down of psychomotor functions, loss of interest, frontal lobe dysfunction, parkinsonism, and delirium. The occurrence of these complications calls for dropping out of IFN treatment or for a significant dose reduction and administration of antidepressants. Efficacy and side effects vary on the basis of the IFN type employed. The aim of our study was to evaluate if the frequency, form, and degree of depression induced are related to the type of IFN employed. We studied 96 patients with chronic hepatitis C. Our study series was divided into four groups according to the type of IFN-alpha administered. Depression degree was clinically evaluated using the Hamilton Depression Rating Scale (HAM-D). All patients were tested before treatment and 1, 3, and 6 months (15 days after the end of treatment) later. Our results showed that the type of IFN used seemed to influence the depression onset rate, with the leukocyte type inducing the lowest level of depression. However, when a number of symptoms associated with the depression were considered, the results of other types of IFN-alpha were found to be better. Use of the most suitable type of IFN-alpha could thus lead to more personalized treatment, with fewer side effects. The type of IFN used seems to influence the psychological side effects and the adaptation rate to therapy. It would be appropriate to choose the type of IFN on the basis of a neuropsychiatric assessment carried out before treatment.
Similar articles
-
[Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].Encephale. 2009 Oct;35(5):477-83. doi: 10.1016/j.encep.2007.09.007. Epub 2008 Jun 12. Encephale. 2009. PMID: 19853722 French.
-
Neuropsychiatric adverse effects of interferon-alpha: recognition and management.CNS Drugs. 2005;19(2):105-23. doi: 10.2165/00023210-200519020-00002. CNS Drugs. 2005. PMID: 15697325 Free PMC article. Review.
-
[Alpha-interferon and mental disorders].Encephale. 2001 Jul-Aug;27(4):308-17. Encephale. 2001. PMID: 11686052 Review. French.
-
Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation.Mol Psychiatry. 2001 Jul;6(4):475-80. doi: 10.1038/sj.mp.4000872. Mol Psychiatry. 2001. PMID: 11443537 Clinical Trial.
-
Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha.Neuropsychobiology. 1998;37(2):93-7. doi: 10.1159/000026485. Neuropsychobiology. 1998. PMID: 9566274 Clinical Trial.
Cited by
-
Somatic pain associated with initiation of interferon-alpha (IFN-α) plus ribavirin (RBV) therapy in chronic HCV patients: A prospective study.Brain Behav Immun Health. 2020 Jan 3;2:100035. doi: 10.1016/j.bbih.2019.100035. eCollection 2020 Feb. Brain Behav Immun Health. 2020. PMID: 34589826 Free PMC article.
-
Citalopram-induced pathways regulation and tentative treatment-outcome-predicting biomarkers in lymphoblastoid cell lines from depression patients.Transl Psychiatry. 2020 Jul 1;10(1):210. doi: 10.1038/s41398-020-00900-8. Transl Psychiatry. 2020. PMID: 32612257 Free PMC article.
-
A New Look at an Old Drug: Cumulative Effects of Low Ribavirin Doses in Amphetamine-Sensitized Rats.Curr Pharm Des. 2020;26(31):3884-3894. doi: 10.2174/1381612826666200326125821. Curr Pharm Des. 2020. PMID: 32213154 Free PMC article.
-
Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder.Curr Pharm Des. 2020;26(4):466-484. doi: 10.2174/1381612826666200115094642. Curr Pharm Des. 2020. PMID: 31939725 Free PMC article. Review.
-
Association of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C.Psychiatry Investig. 2017 May;14(3):314-324. doi: 10.4306/pi.2017.14.3.314. Epub 2017 May 16. Psychiatry Investig. 2017. PMID: 28539950 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical